After a slow 2016, with only 22 new molecular entities, new drug approvals picked back up. Here are the ones that made the grade.

Johnson & Johnson is paying $350 million upfront to join forces with Legend as they look for a working “cure” for certain blood cancers.

Next year will be a busy time for the European Medicines Agency as it looks to complete its move to Amsterdam.

If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.

Will this year’s resurgence be sustained in 2018 in the face of a more uncertain environment?

While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.

The move positions Loxo to wrap up the filing for the Bayer-partnered TRK inhibitor early next year.

Alnylam, which put its hemophilia program on hold in September, has gotten the all-clear from the FDA to resume trials.

Officials want firms to team up to test multiple candidates in single trials, thereby cutting the number of patients who receive placebos.